Literature DB >> 10209961

Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines.

L A Chandler1, B A Sosnowski, L Greenlees, S L Aukerman, A Baird, G F Pierce.   

Abstract

Basic fibroblast growth factor (FGF2) has potent mitogenic and angiogenic activities that have been implicated in tumor development and malignant progression. The biological effects of FGF2 and other members of the FGF ligand family are mediated by 4 transmembrane tyrosine kinase receptors (FGFRs). To better understand the roles of FGFRs in cancer, the expression of FGF2 and each of the 4 FGFRs was assessed by RNase protection analysis of 60 human tumor cell lines, representing 9 tumor types. Expression of at least one FGFR isoform was detected in 90% and FGF2 mRNA in 35% of the cell lines. Our comprehensive analysis of FGF2 and FGFR expression in human tumor cell lines provides evidence that FGF signaling pathways are active in a majority of human tumor cell lines, and lends support to the development of anti-tumor strategies that target FGFRs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10209961     DOI: 10.1002/(sici)1097-0215(19990505)81:3<451::aid-ijc20>3.0.co;2-h

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo.

Authors:  Maria S Aguzzi; Debora Faraone; Daniela D'Arcangelo; Francesco De Marchis; Gabriele Toietta; Domenico Ribatti; Alberto Parazzoli; Paolo Colombo; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  GPC5 gene and its related pathways in lung cancer.

Authors:  Yafei Li; Ping Yang
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

3.  Evaluation of the effect of vector architecture on DNA condensation and gene transfer efficiency.

Authors:  Brenda F Canine; Yuhua Wang; Arash Hatefi
Journal:  J Control Release       Date:  2008-04-23       Impact factor: 9.776

4.  Receptor-mediated gene delivery using polyethylenimine (PEI) coupled with polypeptides targeting FGF receptors on cells surface.

Authors:  Da Li; Qing-qing Wang; Gu-ping Tang; Hong-liang Huang; Fen-ping Shen; Jing-zhong Li; Hai Yu
Journal:  J Zhejiang Univ Sci B       Date:  2006-11       Impact factor: 3.066

5.  Protein arginine methyltransferase 5 is essential for growth of lung cancer cells.

Authors:  Zhongping Gu; Shen Gao; Fahao Zhang; Zhiqiang Wang; Wencai Ma; Richard E Davis; Zhengxin Wang
Journal:  Biochem J       Date:  2012-09-01       Impact factor: 3.857

6.  Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Authors:  Kathryn E Ware; Marianne E Marshall; Lydia R Heasley; Lindsay Marek; Trista K Hinz; Paula Hercule; Barbara A Helfrich; Robert C Doebele; Lynn E Heasley
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

7.  Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells.

Authors:  Clotilde Billottet; Nadia Elkhatib; Jean-Paul Thiery; Jacqueline Jouanneau
Journal:  Mol Biol Cell       Date:  2004-07-28       Impact factor: 4.138

8.  Collagens, stromal cell-derived factor-1alpha and basic fibroblast growth factor increase cancer cell invasiveness in a hyaluronan hydrogel.

Authors:  L David; V Dulong; B Coquerel; D Le Cerf; L Cazin; M Lamacz; J-P Vannier
Journal:  Cell Prolif       Date:  2008-04       Impact factor: 6.831

9.  Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.

Authors:  Lindsay Marek; Kathryn E Ware; Alexa Fritzsche; Paula Hercule; Wallace R Helton; Jennifer E Smith; Lee A McDermott; Christopher D Coldren; Raphael A Nemenoff; Daniel T Merrick; Barbara A Helfrich; Paul A Bunn; Lynn E Heasley
Journal:  Mol Pharmacol       Date:  2008-10-10       Impact factor: 4.436

10.  Perspectives in vector development for systemic cancer gene therapy.

Authors:  Arash Hatefi; Brenda F Canine
Journal:  Gene Ther Mol Biol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.